产品号 #60064_C
Mouse monoclonal IgM antibody against human, rhesus, rabbit TRA-1-60 (podocalyxin)
概述
The TRA‐1‐60R antibody reacts with TRA-1-60 (Podocalyxin), a > 200 kDa pluripotent stem cell-specific protein expressed on the surface of undifferentiated human embryonic stem (ES) and induced pluripotent stem (iPS) cells, embryonal carcinoma (EC) cells and embryonic germ (EG) cells, as well as rhesus monkey ES cell lines. A soluble form of TRA-1-60 has been detected in serum of patients with embryonal carcinoma. The epitope, which is lost upon cell differentiation, contains sialic acid and is associated with a large-molecular-mass transmembrane protein named podocalyxin. Though sialylated, the epitope recognized by the TRA‐1‐60R antibody is resistant to treatment with neuraminidase.
This antibody clone has been verified for labeling human ES and iPS cells grown in TeSR™-E8™ (Catalog #05940), mTeSR™1 (Catalog #85850), and TeSR™2 (Catalog #05860), and for purity assessments of cells isolated with EasySep™ kits, including EasySep™ Human ES/iPS Cell TRA-1-60 Positive Selection Kit (Catalog #18166; partial blocking may be observed) and EasySep™ hESC/hiPSC SSEA-4 Positive Selection Kit (Catalog #18165).
Subtype
Primary Antibodies
Target Antigen
TRA-1-60 (Podocalyxin)
Alternative Names
Podocalyxin, TRA-1
Reactive Species
Human, Rabbit, Rhesus
Conjugation
Alexa Fluor 488, Biotin, PE, Unconjugated
Host Species
Mouse
Cell Type
Pluripotent Stem Cells
Species
Human, Non-Human Primate, Other
Application
Cell Isolation, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Western Blotting
Area of Interest
Stem Cell Biology
Clone
TRA-1-60R
Gene ID
5420
Isotype
IgM, kappa
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (3)
Publications (1)
CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell death & disease 2013
Abstract
Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro 'patient-specific cell-based system' that could facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting conditions and after $\$-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic drug that inhibits Ca(2+)/calmodulin-dependent serine-threonine protein kinase II (CaMKII), drastically reduced the presence of DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system for drug screening and optimization of clinical treatment strategies.
Legal Statement: Alexa Fluor is a registered trademark of Life Technologies Corporation. Antibodies conjugated to Alexa Fluor® are licensed for internal research use only and sale is expressly conditioned on the buyer not using the antibody for manufacturing, performing a service or medical test, or otherwise generating revenue. For use other than research, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
